Most recently, based on data from the ROAR (NCT02034110) (38) and NCI-MATCH (39) basket trials, the FDA granted in June 2022 an accelerated approval of dabrafenib in combination with trametinib for the treatment of patients with BRAF V600E-mutated metastatic or unresectable solid tumors who have progressed on prior treatment and have no other satisfactory treatment options, including thyroid cancers. Here, BRAF is linked to thyroid gland carcinoma.